Zimmer Biomet logged a 0.4% change during today's morning session, and is now trading at a price of $97.41 per share. The S&P 500 index moved 0.0%. ZBH's trading volume is 146,152 compared to the stock's average volume of 1,695,226.
Zimmer Biomet trades -5.35% away from its average analyst target price of $102.92 per share. The 24 analysts following the stock have set target prices ranging from $88.0 to $130.0, and on average have given Zimmer Biomet a rating of hold.
Anyone interested in buying ZBH should be aware of the facts below:
-
Zimmer Biomet's current price is 24.8% above its Graham number of $78.07, which implies that at its current valuation it does not offer a margin of safety
-
Zimmer Biomet has moved -13.3% over the last year, and the S&P 500 logged a change of 12.8%
-
Based on its trailing earnings per share of 4.03, Zimmer Biomet has a trailing 12 month Price to Earnings (P/E) ratio of 24.2 while the S&P 500 average is 29.3
-
ZBH has a forward P/E ratio of 11.3 based on its forward 12 month price to earnings (EPS) of $8.6 per share
-
Its Price to Book (P/B) ratio is 1.51 compared to its sector average of 3.19
-
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide.
-
Based in Warsaw, the company has 17,000 full time employees and a market cap of $19.3 Billion. Zimmer Biomet currently returns an annual dividend yield of 1.0%.
